Table 1.
Available and investigational antibiotics for treatment of MRSA infections
| Agent | Drug class | Killing effect | Marketing authorization EMEA | Marketing authorization FDA | Indications | Route of administration |
|---|---|---|---|---|---|---|
| Vancomycin | Glycopeptide | Bactericidal | Yes | Yes | Standard treatment of MRSA bacteremia | Iv, single daily |
| Teicoplanin | Glycopeptide | Bactericidal | Yes (Authorization not granted in all EU countries) | No | Bacteremia, joint and bone infections. | Iv., im., single daily |
| Tigecycline | Glycylcycline | Bacteriostatic | Yes | Yes | cSSTI, cIAI | Iv, twice daily |
| Linezolid | Oxazolidinone | Bacteriostatic | Yes | Yes | cSSTI, CAP, NP | Iv, po, twice daily |
| Daptomycin | Cyclic lipopeptide | Bactericidal | Yes | Yes | cSSTI, SAB, rIE | Iv., single daily |
| Telavancin | Lipoglycopeptide | Bactericidal | No | Yes | cSSTI | Iv., single daily |
| Dalbavancin | Lipoglycopeptide | Bactericidal | No | No | cSSTI | Iv, once weekly |
| Oritavencin | Lipoglycopeptide | Bactericidal | No | No | cSSTI | Iv. Single daily |
| Ceftobiprole | Cephalosporins | Bactericidal | No | No | cSSTI | Iv, three times daily |
| Ceftaroline | Cephalosporins | Bactericidal | No | No | cSSTI | Iv, single daily |
Abbreviations: Iv, intravenous; po, oral; im, intramuscular; cSSTI, complicated skin and soft-tissue infection; cIAI, complicated intra-abdominal infection; NP, nosocomial pneumonia; CAP, community-acquired pneumonia; SAB, Staphylococcus aureus bacteremia; rIE, right-sided infective endocarditis; EMEA, European Medicines Agency; FDA, US Food and Drug Administration.